Comparative Pharmacology
Head-to-head clinical analysis: IMIPRAMINE PAMOATE versus VIVACTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMIPRAMINE PAMOATE versus VIVACTIL.
IMIPRAMINE PAMOATE vs VIVACTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imipramine is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at presynaptic neuronal membranes, increasing their concentrations in the synaptic cleft. It also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Norepinephrine and serotonin reuptake inhibitor; also has anticholinergic and antihistaminergic activity.
150-300 mg orally once daily at bedtime for depression; 75-150 mg/day for panic disorder.
10 mg orally twice daily (morning and afternoon) or 10 mg once daily at bedtime; may increase gradually to 60 mg/day in divided doses.
None Documented
None Documented
11-25 hours (mean 19 h); extended in elderly (up to 30 h) and hepatic impairment; clinical context: steady-state reached in 7-14 days
Terminal elimination half-life ranges 18–34 hours (mean ~25 hours); clinical steady-state achieved within 5–7 days.
Primarily renal (70% as metabolites, <5% unchanged); 20-30% fecal via biliary excretion
Primarily renal (approximately 70% as metabolites, <5% unchanged), with the remainder via fecal/biliary elimination.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant